

<b>Patient Name</b> VALIDATIONSOFT,HLLFHREPORT	<b>Patient ID</b> SA00061025	<b>Age</b> 52	<b>Gender</b> M	<b>Order #</b> SA00061025
<b>Ordering Phys</b> CLIENT,CLIENT				<b>DOB</b> 11/11/1960
<b>Client Order #</b> SA00061025	<b>Account Information</b>			<b>Report Notes</b>
<b>Collected</b> 08/25/2013 00:00	C7028846-DLMP Rochester SDSC 2 - Client Support			
<b>Printed</b> 10/15/2013 14:36	Rochester, MN 55901			

Test	Flag	Results	Unit	Reference Value	Perform Site*
------	------	---------	------	-----------------	---------------

**Heme Leukemia/Lymphoma; Flow Hold V**
**RECEIVED:** 08/26/2013 15:18 **REPORTED:** 08/27/2013 10:49

Final Diagnosis

MCR

Bone marrow, flow cytometric immunophenotyping:

Cellular bone marrow specimen with increased myeloid lineage blasts, 5%.

## Comment:

There is an increase in myeloid-lineage blasts that, by this analysis, are quantitatively insufficient to warrant an unequivocal diagnosis of acute myeloid leukemia. Blast cell percentages estimated by flow cytometry are affected by specimen processing and gating and, therefore, may differ significantly from those estimated by morphologic review. The differential diagnosis includes acute myeloid leukemia, a myelodysplastic syndrome, a myeloproliferative neoplasm, a treated or recurrent acute leukemia, or sampling bias.

Correlation of the flow cytometry results with the bone marrow aspirate and biopsy findings, clinical history and other laboratory features is required for a definitive diagnosis. If desired, we can provide diagnostic services as part of a hematopathology consultation. Please contact the signing pathologist at 1-800-533-1710 if you have further questions regarding these analyses.

Reviewed by: Steven Bashynski 2013.08.27 10:49:14

Analyte Specific Reagent: This test was developed and its performance characteristics determined by Mayo Clinic. It has not been cleared or approved by the U.S. Food and Drug Administration.

Supplemental PDF Report available at:

<https://test.mmlaccess.com/Reports/C7028846-yKqQYrHx56.ashx>

## Special Studies

MCR

%Lymphs: 10%

## Results:

Blasts: Increased

Express: CD13, CD33, CD117 (partial), CD34, HLA-DR (partial). Do not express: CD10, CD19, CD45. Estimated Size: 5% (total analyzed events-CD45/side scatter)

\*\*\*Performing Site Legend on Last Page of Report\*\*\*

<b>Patient Name</b> VALIDATIONSOFT,HLLFHREPORT	<b>Collection Date and Time</b> 08/25/2013 00:00	<b>Report Status</b> Final
Page 1 of 2		>> Continued on Next Page >>

\* Report times for Mayo performed tests are CST/CDT

<b>Patient Name</b> VALIDATIONSOFT,HLLFHREPORT	<b>Patient ID</b> SA00061025	<b>Age</b> 52	<b>Gender</b> M	<b>Order #</b> SA00061025
<b>Ordering Phys</b> CLIENT,CLIENT				<b>DOB</b> 11/11/1960
<b>Client Order #</b> SA00061025	<b>Account Information</b>			<b>Report Notes</b>
<b>Collected</b> 08/25/2013 00:00	C7028846-DLMP Rochester SDSC 2 - Client Support Rochester, MN 55901			
<b>Printed</b> 10/15/2013 14:36				

Test	Flag	Results	Unit	Reference Value	Perform Site*
B-cells:		No monocytic			
T-cells/NK-cells:		No increase			
Quality Assessment: Specimen received within validated guidelines.					
Flow cytometry analysis performed with antibodies to the following antigens: Triage panel: CD3, CD10, CD16, CD19, CD34, CD45 and kappa and lambda surface light chains. Myeloid 1: CD13, CD15, CD16, CD33, CD34, CD45, CD117 and HLA-DR.					
Microscopic Description					MCR
A submitted Wright-Giemsa slide and a Wright-Giemsa-stained slide prepared from the flow cytometry specimen are examined.					
Flow Cytometry Testing		Performed			MCR

\* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director:
-----	---	---------------

<b>Patient Name</b> VALIDATIONSOFT,HLLFHREPORT	<b>Collection Date and Time</b> 08/25/2013 00:00	<b>Report Status</b> Final
Page 2 of 2		** End of Report **

\* Report times for Mayo performed tests are CST/CDT

**Performing Site:**

Mayo Clinic Laboratories - Rochester Main Campus  
200 First Street SW, Rochester MN 55905  
Franklin R. Cockerill, M.D. Lab Director  
Phone: 800-533-1710  
<http://www.mayomedicallaboratories.com>

**VALIDATIONSOFT, HLLFHREPORT**

**MEDICAL RECORD # (PATIENT ID) SA00061025**

DOB	11/11/1960	CLIENT ID/WARD	7028846	ORDER #	B326000380
SEX	Male	CLIENT/NAME WARD	DLMP Rochester	CLIENT ORDER #	SA00061025
CLIENT MRN	SA00061025	CITY, ST, ZIP	Rochester	DATE COLLECTED	8/25/2013 12:00 AM
REQUESTED BY	CLIENT CLIENT	MN	55901	DATE RECEIVED	8/26/2013 3:18 PM
				DATE REPORTED	8/27/2013 10:49 AM

**Heme Leukemia/Lymphoma; Flow Hold V**

**Final Diagnosis:**

Bone marrow, flow cytometric immunophenotyping:

cellular bone marrow specimen with increased myeloid lineage blasts, 5%.

**Comment:**

There is an increase in myeloid-lineage blasts that, by this analysis, are quantitatively insufficient to warrant an unequivocal diagnosis of acute myeloid leukemia. Blast cell percentages estimated by flow cytometry are affected by specimen processing and gating and, therefore, may differ significantly from those estimated by morphologic review. The differential diagnosis includes acute myeloid leukemia, a myelodysplastic syndrome, a myeloproliferative neoplasm, a treated or recurrent acute leukemia, or sampling bias.

Correlation of the flow cytometry results with the bone marrow aspirate and biopsy findings, clinical history and other laboratory features is required for a definitive diagnosis. If desired, we can provide diagnostic services as part of a hematopathology consultation. Please contact the signing pathologist at 1-800-533-1710 if you have further questions regarding these analyses.

Reviewed by: Steven Bashynski 2013.08.27 10:49:14

**Special Studies:**

%Lymphs: 10%

**Results:**

Blasts: Increased

Express: CD13, CD33, CD117 (partial), CD34, HLA-DR (partial).

Do not express: CD10, CD19, CD45.

Estimated Size: 5% (total analyzed events-CD45/side scatter)

B-cells: No monotypic

T-cells/NK-cells: No increase

Quality Assessment: Specimen received within validated guidelines.

Flow cytometry analysis performed with antibodies to the following antigens:

Triage panel: CD3, CD10, CD16, CD19, CD34, CD45 and kappa and lambda surface light chains.

Myeloid 1: CD13, CD15, CD16, CD33, CD34, CD45, CD117 and HLA-DR.

**Microscopic Description:**

A submitted wright-Giemsa slide and a wright-Giemsa-stained slide prepared from the flow cytometry specimen are examined.

**VALIDATIONSOFT, HLLFHREPORT**

MEDICAL RECORD # (PATIENT ID) SA00061025

DOB	11/11/1960	CLIENT ID/WARD	7028846	ORDER #	B326000380
SEX	Male	CLIENT/NAME WARD	DLMP Rochester	CLIENT ORDER #	SA00061025
CLIENT MRN	SA00061025	CITY, ST, ZIP	Rochester	DATE COLLECTED	8/25/2013 12:00 AM
REQUESTED BY	CLIENT CLIENT	MN	55901	DATE RECEIVED	8/26/2013 3:18 PM
				DATE REPORTED	8/27/2013 10:49 AM

**Disclaimer:**

Analyte Specific Reagent: This test was developed and its performance characteristics determined by Mayo Clinic. It has not been cleared or approved by the U.S. Food and Drug Administration.

R3Q45 Report